TABLE 1.
Baseline Demographic and Clinical Characteristics of the Study Population (n = 154)
| Age (yrs) | 72.1 ± 9.4 |
| Age >75 yrs | 70 (45) |
| Male | 96 (62) |
| Hypertension | 125 (81) |
| Diabetes mellitus | 56 (36) |
| History of heart failure | 53 (34) |
| Peripheral arterial disease | 21 (14) |
| Prior CVA/TIA | 58 (38) |
| Prior hemorrhagic CVA | 21 (14) |
| Prior major bleed or propensity for bleeding | 96 (62) |
| Labile INR measurements | 31 (20) |
| Concomitant chronic NSAID use | 22 (14) |
| Liver disease | 9 (6) |
| Renal disease | 14 (9) |
| Significant alcohol consumption | 16 (10) |
| CHADS2 score | 3 (2–4) |
| CHA2DS2VASC score | 4 (3–5) |
| HAS-BLED score | 3 (2–4) |
| CHADS2 score | 2.8 ± 1.4 |
| CHA2DS2VASC score | 4.1 ± 1.6 |
| HAS-BLED score | 3.2 ± 1.2 |
Values are mean ± SD, n (%), or median (interquartile range).
CHADS2 = congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA or thromboembolism (doubled); CHA2DS2VASC = congestive heart failure, hypertension, age ≥75 years [doubled], diabetes mellitus, prior stroke or TIA or thromboembolism [doubled], vascular disease, age 65 to 74 years, sex category; CVA = cerebrovascular accident; HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly; INR = international normalized ratio; IQR = interquartile range; NSAID = nonsteroidal anti-inflammatory drug; TIA = transient ischemic attack.